Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis

Recommendation ID: IPG631/1
Question: Further research on subcutaneous automated low-flow pump implantation for refractory ascites should report details of patient selection, the frequency of pump-related complications, and the need for regular albumin infusions.
Any explanatory notes (if applicable): Current evidence on the safety of subcutaneous automated low-flow pump implantation for refractory ascites shows there are serious but well-recognised safety concerns, including device failure and acute kidney injury. Evidence on efficacy is limited in quantity. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

Source guidance details

Comes from guidance: Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis
Number: IPG631
Date issued: November 2018

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	30/11/2018